ClinicalTrials.gg

Program

Neuroaid

Also written as “MLC901”, “MLC 901” and “NeuroAiD”.

Its studies are mostly in Ischemic Stroke · Alzheimer Disease · Spinal Cord Injuries · Brain Injuries, Traumatic · Cerebral Infarction, led by 2 companies.

Furthest: phase 4, since Aug 27, 20155 company-led studies, 2 open or runningNext primary completion: Sep 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Moleac Pte41 open or runningphase 4since Aug 27, 2015Jul 22, 2008Feb 2029phase 3 · NCT07191028
EVD Pharmacy and Medical11 open or runningphase 4since Sep 14, 2026Sep 14, 2026Sep 2027phase 4 · NCT07828210

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 22, 2008First study: phase 2 study in StrokeNew to Moleac PteMoleac Pte · NCT00721825 · 40 enrolled · Singapore
  2. Aug 27, 2015Phase 4 study in Spinal Cord InjuriesMoleac Pte · NCT02537899 · 30 enrolled · Malaysia
  3. Apr 19, 2021Phase 3 study in Brain Injuries, TraumaticMoleac Pte · NCT04861688 · 182 enrolled · Russian Federation
  4. Sep 2, 2025Phase 3 study in Alzheimer DiseaseMoleac Pte · NCT07191028 · 350 planned · Singapore
  5. Sep 14, 2026EVD Pharmacy and Medical's first study: phase 4 study in StrokeNew to EVD Pharmacy and MedicalEVD Pharmacy and Medical · NCT07828210 · 80 planned · Vietnam

Ahead

  1. Sep 2027Primary completion: phase 4 study in StrokeEVD Pharmacy and Medical · NCT07828210
  2. Feb 2029Primary completion: phase 3 study in Alzheimer DiseaseMoleac Pte · NCT07191028

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07828210Stroke · Vietnam4RecruitingEVD Pharmacy and MedicalSep 202780
NCT07191028Alzheimer Disease · Singapore3Not yet recruitingMoleac PteFeb 2029350
NCT04861688Brain Injuries, Traumatic · Russian Federation3CompletedMoleac PteFeb 14, 2023182
NCT02537899Spinal Cord Injuries · Malaysia4CompletedMoleac PteSep 20, 202330
NCT00721825Stroke · Singapore2CompletedMoleac PteJul 200840

How it is read

Names in the registry

  • “MLC901”, 1 entry
  • “MLC 901”, 1 entry
  • “NeuroAiD”, 1 entry
  • “Traditional Chinese Medicine (NeuroAiD II™ (MLC901)”, 1 entry
  • “Neuroaid”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.